Style | Citing Format |
---|---|
MLA | Ashraf MA, et al.. "The Application of Direct Viral Cytopathic Hypothesis to Design Drug Trials in the Battle Against Covid-19." DARU# Journal of Pharmaceutical Sciences, vol. 28, no. 2, 2020, pp. 813-814. |
APA | Ashraf MA, Sherafat A, Pourdast A, Nazemi P, Mohraz M (2020). The Application of Direct Viral Cytopathic Hypothesis to Design Drug Trials in the Battle Against Covid-19. DARU# Journal of Pharmaceutical Sciences, 28(2), 813-814. |
Chicago | Ashraf MA, Sherafat A, Pourdast A, Nazemi P, Mohraz M. "The Application of Direct Viral Cytopathic Hypothesis to Design Drug Trials in the Battle Against Covid-19." DARU# Journal of Pharmaceutical Sciences 28, no. 2 (2020): 813-814. |
Harvard | Ashraf MA et al. (2020) 'The Application of Direct Viral Cytopathic Hypothesis to Design Drug Trials in the Battle Against Covid-19', DARU# Journal of Pharmaceutical Sciences, 28(2), pp. 813-814. |
Vancouver | Ashraf MA, Sherafat A, Pourdast A, Nazemi P, Mohraz M. The Application of Direct Viral Cytopathic Hypothesis to Design Drug Trials in the Battle Against Covid-19. DARU# Journal of Pharmaceutical Sciences. 2020;28(2):813-814. |
BibTex | @article{ author = {Ashraf MA and Sherafat A and Pourdast A and Nazemi P and Mohraz M}, title = {The Application of Direct Viral Cytopathic Hypothesis to Design Drug Trials in the Battle Against Covid-19}, journal = {DARU# Journal of Pharmaceutical Sciences}, volume = {28}, number = {2}, pages = {813-814}, year = {2020} } |
RIS | TY - JOUR AU - Ashraf MA AU - Sherafat A AU - Pourdast A AU - Nazemi P AU - Mohraz M TI - The Application of Direct Viral Cytopathic Hypothesis to Design Drug Trials in the Battle Against Covid-19 JO - DARU# Journal of Pharmaceutical Sciences VL - 28 IS - 2 SP - 813 EP - 814 PY - 2020 ER - |